Adebrelimab
Advanced Refractory Solid Tumors
Second Affiliated Hospital of Soochow UniversityPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 89/ 100
Competitive context
8 Active assets in the Advanced Refractory Solid Tumors cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Durvalumab Second Affiliated Hospital of Soochow University | Phase 2 | BB |
Sugemalimab Second Affiliated Hospital of Soochow University | Phase 2 | BB |
Gm-Csf Second Affiliated Hospital of Soochow University | Phase 2 | B |
Talzenna St. Jude Children's Research Hospital | Phase 2 | B |
Regorafenib China Medical University, China | Phase 1/2 | CCC |
View all 12 →
Same molecule, other indications
Adebrelimab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →